Explore ›
Finding
Finding
improvement
Systemic delivery of anti-miR-33 in African green monkeys induced a sustained 50% increase in plasma HDL cholesterol over 12 weeks, with corresponding increases in HDL-associated apolipoproteins AI and AII and larger HDL particles, demonstrating that pharmacological inhibition of both miR-33a and miR-33b is an effective strategy for raising HDL in a model highly relevant to humans.
| Effect size | 50% increase in HDL cholesterol at 8 weeks, sustained through 12 weeks |
| Follow-up | 12 weeks |
| Comparator | Mismatch control antisense oligonucleotide (same dose, same schedule) |
| Effect summary | improvement; 50% increase in HDL cholesterol at 8 weeks, sustained through 12 weeks |
| Effect modifiers | [{"modifier": "diet (chow vs high-carbohydrate moderate-cholesterol)", "interaction_p": "", "direction": "null", "stratum_details": "ABCA1 derepression sustained under both dietary conditions; HDL increase observed across both diet phases", "plain_language": "The HDL-raising effect persisted even after switching to an unhealthy high-carbohydrate diet", "annotation_notes": "Under high-carb diet, SREBF1 and miR-33b were upregulated 5-fold and 2.2-fold respectively, making miR-33b expression >7-fold higher than miR-33a. Despite this, anti-miR-33 maintained target gene derepression."}] |
Connected entities
Interventions
Conditions
Outcomes
Source
PMC3235584
Inhibition of miR-33a/b in non-human primates raises plasma HDL and reduces VLDL triglycerides